| Fund ID | 805-4551094035 |
| Fund type | Venture Capital Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 0% |
| Owned by the adviser or related persons | 1% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 99% |
| Fund | Type | Gross assets |
|---|---|---|
| Oncology Impact Fund 2, L.P. | Other Private | $1.01B |
| UBS Oncology Impact Fund L.P. | Other Private | $629.7M |
| Mpm Bioventures 2018, L.P. | Venture Capital | $548.7M |
Mpm Bio 2014 Nvs Strategic Fund, L.P. reports $5.7 million in gross assets, among the top 83% of private funds by size.
The stated minimum investment is $100,000.
Mpm Bio 2014 Nvs Strategic Fund, L.P. is managed by Mpm Asset Management LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.